Covaxin effective against Alpha, Delta variants, says U.S. body

“Results from two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the United Kingdom and India, respectively,” the US’ National Institute of Health (NIH)

Bharat Biotech’s Covaxin, which was developed in collaboration with the Indian Council of Medical Research and National Institute of Virology, generates antibodies that effectively neutralise both Alpha and Delta variants of Covid-19, the US’ National Institute of Health (NIH) has said.

A health worker holding up a vial of Covaxin. (Sanchit Khanna / HT Photo)

“Results from two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the United Kingdom and India, respectively,” a statement by the top American health research institute on its official website read on Tuesday.

(With agency inputs)